Related Experiment Videos
Interferon therapy for metastatic renal cell carcinoma
1Department of Urology, University of Texas M.D. Anderson Cancer Center, and Tumor Institute, Houston 77030.
Seminars in Surgical Oncology
|January 1, 1988
Summary
Interferon therapy shows activity against metastatic renal cell carcinoma. However, optimal treatment protocols, including interferon type, dose, and schedule, require further clinical investigation for this cancer.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Metastatic renal cell carcinoma (mRCC) is a significant health concern.
- Interferon-based therapies have been explored for mRCC treatment.
Purpose of the Study:
- To evaluate the efficacy of various interferon protocols in patients with metastatic renal cell carcinoma.
Main Methods:
- A total of 274 patients with mRCC were treated with different interferon regimens.
- Leukocyte (alpha) interferon and recombinant alpha interferon were administered to patient cohorts.
Main Results:
- Leukocyte (alpha) interferon achieved a 26% response rate (3 complete responses, 10 partial responses) in 50 patients.
- Recombinant alpha interferon showed a similar response rate (21%) in 89 patients.
- Combinations of interferon with chemotherapy or other biologic agents did not yield superior outcomes.
Conclusions:
- Interferon demonstrates clear activity against renal cell carcinoma.
- Further clinical research is needed to determine the optimal interferon type, dosage, and treatment schedule for mRCC.